Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration

Pharmicell Co., Ltd.100 enrolled

Overview

This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

100

Conditions

Acute Myocardial Infarction

Interventions

Hearticellgram-AMIBIOLOGICAL

Patients who had administered Hearticellgram-AMI.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Those who had administered Hearticellgram-AMI 2. Those who voluntarily agreed in writing to participate in this investigation Exclusion Criteria: \-

Locations (1)

KIMHYUNSOO Clinic

Seoul, Gangnam, South Korea

RECRUITING

Outcomes

Primary Outcomes

Rate of AESI

death, neoplasms or malignancies in tissues or organs, Immune response

Time frame: For 5 years

Central Contacts

DAEUN JUNG

CONTACT

82-2-3496-0134 daeun4100@pharmicell.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.